Investor profile
Kirk Nielsen
Private equity, Venture capital & Managing Director at Versant Ventures, Co-Founder & Managing Partner at Vensana Capital
Kirk Nielsen is a Co-Founder & Managing Partner at Vensana Capital, whose known portfolio counts 10 companies.
Is Kirk Nielsen a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- HardwareHealthcare
Contacts
Affiliated funds' portfolios
Managing Director at Versant Ventures, whose known portfolio counts 10 companies
- Dualitas Therapeutics
- Light Horse Therapeutics
- 858 Therapeutics
- AllRock Bio
- Antag Therapeutics
- Granite Bio
- Helicore Biopharma
- Dayra Therapeutics
- Gate Bioscience
- Pep2Tango Therapeutics
Co-Founder & Managing Partner at Vensana Capital, whose known portfolio counts 10 companies
- Apella Technology
- SpyGlass Pharma
- Alleviant Medical
- Ventaris Surgical
- Okami Medical
- Elucent Medical
- Evident Vascular
- Luna Diabetes
- iVEAcare
- Volta Medical
Investor Profile
The listing covers sectors Hardware and Healthcare, and focus areas Biotech, Diagnostics, Digital Health and Drug Delivery. Startups operating in these areas may find Kirk Nielsen relevant.
Stage-wise, the deals at Vensana Capital cluster around Growth, Seed and Series A rounds.
What the affiliated firm has backed is the closest available signal on whether Kirk Nielsen is worth approaching.
Colleagues
Showing 20 of 30
Markus Warmuth
Venture Partner
Cambridge, United States
Robin Praeger
Managing Director/Advisor
San Francisco, United States
Carlo Rizzuto
Managing Director
New York, United States
Joel Drewry
Principal
Toronto, Canada
Clare Ozawa
Managing Director
San Diego, United States
Jerel Davis
Managing Director
Vancouver, Canada
Maria Berkman
Partner
Boston, United States
Amrinder Singh
Partner
Minneapolis, United States
Beckie Robertson
Founder and General Partner
Palo Alto, United States
Greg Banker
Partner
Minneapolis, United States
Rami Hannoush
Investor
San Francisco, United States
Charles Warden
Managing Director
Burlingame, United States
Don Milder
Managing Partner
Laguna Beach, United States
Ross Jaffe
Managing Director
Los Angeles, United States
Sam Colella
VC
Los Altos, United States
Bill Link
Investor
Irvine, United States
Nikita Sharma
Principal
Basel, Switzerland
Tom Woiwode
Managing Director
San Francisco, United States
Alexander Mayweg
Managing Director
Basel, Switzerland
Guido Magni
Partner
Basel, Switzerland
Frequently asked questions
Who is Kirk Nielsen?
Kirk Nielsen is a private equity investor and venture capital investor based in Minneapolis, Minnesota, United States, listed as Co-Founder & Managing Partner at Vensana Capital. The known portfolio of that firm counts 10 companies. That portfolio belongs to the firm, not to Kirk Nielsen personally.
What does Kirk Nielsen invest in?
Listed sectors include Hardware and Healthcare; listed focus areas include Biotech, Diagnostics, Digital Health and Drug Delivery. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Kirk Nielsen invest at?
Vensana Capital appears in Growth, Seed and Series A rounds across its known deals, and Kirk Nielsen is listed there as Co-Founder & Managing Partner. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Kirk Nielsen listed at?
Kirk Nielsen is listed as Co-Founder & Managing Partner at Vensana Capital. 30 other people in the database share a firm with Kirk Nielsen.
How do I contact Kirk Nielsen?
An email address, a phone number and a LinkedIn page are on file for Kirk Nielsen. The address stays masked on this page and is readable inside RaiseHunt after you create an account.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal